NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...
Should Alzheimer’s be diagnosed without symptoms? Proposal to rely on blood tests roils scientists
Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...
A groundbreaking study from the University of California has hinted that following a keto diet might just be the secret to ...
New research from Scripps Research links Alzheimer’s disease and alcohol use disorder, showing similar gene expression ...
Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...
Six years after his Alzheimer’s diagnosis, 90-year-old Zelik Bocknek (Zel) refuses to slow down — and he believes his active lifestyle is key to keeping his symptoms at bay.
Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
GlobalData on MSN8h
Veravas and Phanes Biotech to develop tau pathology test for Alzheimer’sVeravas and Phanes Biotech have announced a partnership for the joint development of a blood-based tau pathology test for ...
Neurologist Dona Murphey, the founder of website PrognosUs, hopes her platform can give caregivers a place to find support in ...
The Hearty Soul on MSN8h
These Nutrients Are Lower In Alzheimer's Patients, StudyAlzheimer's disease is a progressive neurodegenerative disease that affects millions of people worldwide. Oxidative stress ...
John Reichart says he's been assembling Christmas decor in his garage since September. On Thursday, the final lawn ornament ...
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback